SCHOTT Pharma Updates FY 2025 Revenue and EBITDA Guidance

SCHOTT Pharma AG & Co. KGaA has released an update for its fiscal year 2025 projections, focusing on revenue growth and the EBITDA margin. The company anticipates organic revenue growth to hover around 6.0%, marking the lower edge of its expected range of 6.0% to 9.0%, described as "high-single digit." This revised outlook is derived from preliminary outcomes observed during the first nine months of 2025 and the complete fiscal year prognosis.

Additionally, SCHOTT Pharma projects an increase in its EBITDA margin to about 28.0%, surpassing its previous benchmark set at approximately 26.9% in FY 2024. This positive adjustment points to improved financial health and operational efficiency.

The detailed Q3/9M 2025 financial results will be publicly available on August 12, 2025, providing further insights into the company's performance. SCHOTT Pharma remains committed to transparency and investor communication through these updates.